# TAU N279K Research Report **Protein:** TAU N279K **Variant:** N279K **UniProt ID:** P10636 **Disease Association:** Alzheimer's disease **Report Generated:** 2026-07-28 13:14 UTC **AlphaFold Confidence (pLDDT):** 54.3% **Structure Folded:** 2026-06-17 --- ## Structure Summary Tau is a protein that normally stabilizes brain cell structures but forms toxic clumps in Alzheimer's disease. This analysis examined the N279K variant (where asparagine at position 279 is replaced by lysine) using computational structure prediction, revealing an overall low confidence score of 54.3 that indicates highly uncertain structural predictions. The low confidence prevents drawing definitive conclusions about how this specific mutation affects tau's structure or disease progression. --- Tau is a microtubule-associated protein essential for stabilizing the structural scaffolding inside neurons. In Alzheimer's disease and related dementias, tau detaches from microtubules and aggregates into beta-sheet-rich fibrils that accumulate in brain cells [2]. Different tau variants have been associated with various neurodegenerative diseases, with specific mutations affecting tau's propensity to aggregate and cause neuronal dysfunction. The N279K variant involves substitution of asparagine (a polar, uncharged amino acid) with lysine (a positively charged amino acid) at position 279 of the tau protein. This position falls within tau's proline-rich region, which normally mediates protein-protein interactions and influences tau's conformational flexibility. The computational structure prediction of N279K tau yielded an average confidence score (pLDDT) of 54.3, which falls well below the 70 threshold generally considered reliable for structural interpretation. This very low confidence indicates that the predicted structural model contains substantial uncertainty and should not be used to draw firm conclusions about the mutation's structural effects. The low confidence likely reflects intrinsic disorder in tau protein, which lacks a stable folded structure under physiological conditions and instead adopts multiple dynamic conformations [2]. Tau's intrinsically disordered nature makes it particularly challenging for structure prediction algorithms, which are optimized for well-folded proteins. Without experimental validation through techniques like solid-state NMR spectroscopy or cryo-electron microscopy of fibrillar assemblies, the structural impact of N279K remains speculative. Clinical context for this specific variant is limited in the available literature. While tau phosphorylation at various sites serves as a biomarker for Alzheimer's disease diagnosis [1], and tau accumulation drives synapse loss and neurodegeneration in tauopathies [3], the N279K variant has not been extensively characterized in published studies. The introduction of a positive charge at position 279 could theoretically alter tau's interactions with microtubules or influence its aggregation propensity, but experimental studies would be required to test these hypotheses. Future research combining biochemical characterization, aggregation assays, and structural biology techniques would be needed to understand whether N279K contributes to disease pathology. ## Works Cited [1] Chai et al. (2026). Plasma p-tau as a biomarker for the differential diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Alzheimer's research & therapy. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42252466/) [2] El et al. (2026). Structures and Dynamics of Tau Assemblies from Solid-State NMR. Accounts of chemical research. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42283695/) [3] Nimmo et al. (2026). Dysregulation of complement at the synapse in P301S mice and human tauopathies. Acta neuropathologica communications. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42271460/) ## Similar Research **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.** Gerlando et al. (2026) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | frontotemporal dementia | 0.789 | genetic_literature, clinical, literature, genetic_association, animal_model | | Pick disease | 0.757 | literature, animal_model, genetic_association, genetic_literature | | supranuclear palsy, progressive, 1 | 0.725 | literature, animal_model, genetic_association, genetic_literature | | Progressive supranuclear palsy - parkinsonism | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Atypical progressive supranuclear palsy | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Classical progressive supranuclear palsy | 0.696 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy-parkinsonism syndrome | 0.647 | animal_model, genetic_association, genetic_literature | | late-onset Parkinson disease | 0.639 | literature, animal_model, genetic_association, genetic_literature | | semantic dementia | 0.639 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy | 0.614 | genetic_literature, clinical, literature, genetic_association, animal_model | *...and 3339 more associations* --- ## Agent Findings ### Literature (1) - **2026-06-18:** None of the provided papers are directly relevant to the TAU N279K variant specifically. While several papers discuss tau pathology, MAPT gene regulation, and genetic variants in Alzheimer's disease, none explicitly investigate or mention the N279K amino acid substitution in the tau protein, which would be essential for understanding this particular variant's role in disease. ### Clinical (1) - **2026-06-18:** First baseline data collection ### Structural (1) - **2026-06-18:** AlphaFold structure update: Baseline check: 9 structure(s) found ### Synthesis (1) - **2026-06-18:** Synthesis of 1 findings (peptides): The TAU N279K variant associated with Alzheimer's disease demonstrates substantial druggability pote... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)